Publication:
Evaluation of a pharmacogenetic test in thailand for abacavir hypersensitivity screening in human immunodeficiency virus infection

dc.contributor.authorChonlaphat Sukasemen_US
dc.contributor.authorMontchai Gatrungseien_US
dc.contributor.authorSomying Promsoen_US
dc.contributor.authorPhillip Cunninghamen_US
dc.contributor.authorNapatrupron Koomdeeen_US
dc.contributor.authorSiwalee Santonen_US
dc.contributor.authorMontri Chamnanphonen_US
dc.contributor.authorInsee Sensornen_US
dc.contributor.authorWasun Chantratitaen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherKirby Instituteen_US
dc.date.accessioned2018-10-19T04:43:59Z
dc.date.available2018-10-19T04:43:59Z
dc.date.issued2013-01-01en_US
dc.description.abstractAbacavir hypersensitivity reaction (ABC-HSR) is associated with the presence of HLA-B* 57:01 allele. Alternative tests for ABC-HSR associated allele determination are needed where sequence-based HLA typing is not available, particularly in resource-limited settings or developing countries. This study focused on the development and evaluation of two HLA-B* 57:01 tagging SNPs (single nucleotide polymorphism) HCP5 (HLA complex P5) rs2395029 and TNF (tumor necrosis factor) rs3093726 genotyping assays. Two hundred and thirteen purified genomic DNA samples were used to evaluate the performance characteristics of a HLA-B* 57:01 screening method based on allele-specific polymerase chain reaction (AS-PCR) with melting curve analysis. HCP5 rs2395029 and TNF rs3093726 were also genotyped using simple probe real-time PCR assay. All samples were successfully genotyped wherein AS-PCR genotyping provided 100% sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) when compared with specific HLA-B status by sequencing based assay. When comparing the AS-PCR screening method with the HCP5 rs2395029 and TNF rs3093726 genotyping method, the former had 100% sensitivity, 100% specificity, 100% PPV and 100% NPV using a simple probe; while the latter one had 95.24% sensitivity, 100% specificity, 100% PPV and 99.48% NPV, respectively. In conclusion, our study lends support on a molecular tool for pharmacogenetic screening in resource-limited settings. Thus, serious drug hypersensitivity associated with ABC may potentially be reduced in Thailand by further evaluation of the proposed assay in clinical practice. © 2013 Bentham Science Publishers.en_US
dc.identifier.citationCurrent Pharmacogenomics and Personalized Medicine. Vol.11, No.3 (2013), 231-236en_US
dc.identifier.doi10.2174/18756921113119990005en_US
dc.identifier.issn18756913en_US
dc.identifier.issn18756921en_US
dc.identifier.other2-s2.0-84888086737en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/123456789/31420
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84888086737&origin=inwarden_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.subjectMedicineen_US
dc.subjectPharmacology, Toxicology and Pharmaceuticsen_US
dc.titleEvaluation of a pharmacogenetic test in thailand for abacavir hypersensitivity screening in human immunodeficiency virus infectionen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84888086737&origin=inwarden_US

Files

Collections